Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
13 09 2023
Historique:
pmc-release: 13 09 2024
medline: 15 9 2023
pubmed: 13 9 2023
entrez: 13 9 2023
Statut: ppublish

Résumé

Infection with chronic hepatitis C virus (HCV) is an important risk factor for hepatocellular carcinoma (HCC). Direct-acting antiviral therapy has transformed care for patients with HCV and reduces the risk of HCC. Despite HCV cure, a residual HCC risk remains in patients with advanced fibrosis and cirrhosis, with multiple mechanisms underlying subsequent hepatocarcinogenesis. Transcriptomic and proteomic signatures demonstrate the capacity for HCC risk stratification, and chemoprevention strategies are emerging. For now, pending more precise stratification, HCC surveillance of patients with cured HCV and advanced fibrosis or cirrhosis should continue.

Identifiants

pubmed: 37703341
pii: 7273013
doi: 10.1093/infdis/jiac447
pmc: PMC10499186
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

S226-S231

Subventions

Organisme : NIDDK NIH HHS
ID : T32 DK007191
Pays : United States
Organisme : NIH HHS
ID : 5T32DK007191-48
Pays : United States

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
Hepatology. 2020 Dec;72(6):1912-1923
pubmed: 32762045
Lancet. 2019 Apr 6;393(10179):1453-1464
pubmed: 30765123
Hepatol Commun. 2022 Sep;6(9):2581-2593
pubmed: 35712812
Gastroenterology. 2013 May;144(5):1024-30
pubmed: 23333348
Hepatology. 2005 May;41(5):1096-105
pubmed: 15841445
Gastroenterology. 2019 Jun;156(8):2313-2329.e7
pubmed: 30836093
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Hepatol. 2016 Oct;65(1 Suppl):S120-S129
pubmed: 27641982
JAMA. 2014 Nov 12;312(18):1927-8
pubmed: 25387192
Hepatology. 2021 Apr;73(4):1275-1289
pubmed: 32659847
Hepatology. 2022 Jun;75(6):1420-1428
pubmed: 34779535
J Hepatol. 2017 Dec;67(6):1204-1212
pubmed: 28802876
Hepatology. 2018 Jun;67(6):2244-2253
pubmed: 29205416
J Hepatol. 2010 Jul;53(1):36-42
pubmed: 20400197
Ann Intern Med. 2019 Sep 3;171(5):318-327
pubmed: 31426090
J Gen Virol. 2015 Aug;96(8):2133-2144
pubmed: 25872741
Gastroenterology. 1997 Feb;112(2):463-72
pubmed: 9024300
Pathol Biol (Paris). 2010 Aug;58(4):258-66
pubmed: 20116937
Gastroenterology. 2018 Nov;155(5):1436-1450.e6
pubmed: 30031138
Gut. 2015 Aug;64(8):1296-302
pubmed: 25143343
Hepatology. 2016 Nov;64(5):1442-1450
pubmed: 27015107
Hepatology. 2019 Feb;69(2):487-497
pubmed: 28749564
Clin Gastroenterol Hepatol. 2010 Feb;8(2):192-9
pubmed: 19879972
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Gastroenterology. 2017 Oct;153(4):996-1005.e1
pubmed: 28642197
Hepatology. 2019 Mar;69(3):1032-1045
pubmed: 30289989
J Hepatol. 2017 Sep 05;:
pubmed: 28887168
J Hepatol. 2022 Apr;76(4):812-821
pubmed: 34871626
J Natl Cancer Inst. 2020 Mar 1;112(3):286-294
pubmed: 31168595
Lancet. 2019 Oct 19;394(10207):1451-1466
pubmed: 31631857
Gastroenterology. 2011 Jul;141(1):141-9
pubmed: 21440548
Hepatology. 2010 Sep;52(3):833-44
pubmed: 20564351
N Engl J Med. 2020 Mar 12;382(11):1018-1028
pubmed: 32160663
Clin Infect Dis. 2015 Sep 1;61(5):730-40
pubmed: 25987643
Nat Rev Microbiol. 2007 Jun;5(6):453-63
pubmed: 17487147
Gastroenterology. 2019 May;156(6):1683-1692.e1
pubmed: 30660729
JAMA Netw Open. 2020 Sep 1;3(9):e2015626
pubmed: 32870314
Gastroenterology. 2019 Nov;157(5):1264-1278.e4
pubmed: 31356807
Med. 2021 Jul 09;2(7):836-850.e10
pubmed: 34318286
Hepatology. 2022 Jul;76(1):139-154
pubmed: 35030279
J Hepatol. 2020 Aug;73(2):277-284
pubmed: 32145260
N Engl J Med. 2008 Nov 6;359(19):1995-2004
pubmed: 18923165
Gastroenterology. 2004 Oct;127(4):1110-22
pubmed: 15480989
Am J Gastroenterol. 2022 Sep 1;117(9):1409-1411
pubmed: 35973179
Oncotarget. 2018 Feb 27;9(20):15350-15364
pubmed: 29632649
J Hepatol. 2021 Nov;75(5):1049-1057
pubmed: 34097994
Eur J Cancer Prev. 2017 Sep;26(5):368-377
pubmed: 27111112
Nat Med. 2011 May;17(5):589-95
pubmed: 21516087
Cancer Cell. 2016 Dec 12;30(6):879-890
pubmed: 27960085
J Hepatol. 2016 Oct;65(4):719-726
pubmed: 27084592
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
JAMA Intern Med. 2014 Feb 1;174(2):204-12
pubmed: 24193887

Auteurs

Eric M Przybyszewski (EM)

Liver Center and Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

Raymond T Chung (RT)

Liver Center and Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH